Helicobacter pylori infection
Conditions
Interventions
EBAC group:Esomeprazole 20mg bid + bismuth potassium citrate 220mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid for 14 days
EBAX group:Esomeprazole 20mg bid + bismuth potassium citrate 220mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid/levofloxacin 500mg qd/tetracycline 500mg tid for 14 days
EBAL group:Esomeprazole 20mg bid + bismuth potassium citrate 220mg bid + amoxicillin 1g bid + levofloxacin 500mg qd for 14 days
R-EBAX group:Esomeprazole 20mg bid + bismuth potassium citrate 220mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid/levofloxacin 500mg qd/tetracycline 500mg tid for 14 days
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-65 years, male or female; (2) The presence of Hp infection as evidenced by a positive C13 or C14 breath test, rapid urease test, or histopathology; (3) No penicillin or amoxicillin allergy; (4) No history of allergy to other drugs in the study protocol; (5) Consent to gastroscopy and biopsy for histopathology; (6) Signed consent to participate in the study voluntarily, actively cooperate with the follow-up, and bear the related medical expenses.
Exclusion criteria
Exclusion criteria: (1) Presence of active gastrointestinal bleeding; (2) History of previous upper gastrointestinal surgery; (3) Pregnant and lactating women and those who are unwilling to use contraception during the trial period; (4) Patients with other concurrent serious diseases that affect the evaluation of this study, such as severe liver disease, lung disease, heart disease, kidney disease, malignant tumors, and alcoholism disorders; (5) Patients who are unable to express their complaints correctly, such as psychosis, severe neurosis, and are unable to cooperate with this test; (6) History of allergy to the test drug; (7) Those who are unable or unwilling to provide informed consent; (8) The presence of other factors that, in the opinion of the investigator, may affect the accuracy of the test results and the interests of the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance;The incidence of adverse reactions;Safety; | — |
Countries
China
Contacts
Public ContactZibin Tian
The Affiliated Hospital of Qingdao University
Outcome results
None listed